2-ethyl-2H-indazole | 43120-23-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-ethyl-2H-indazole
• 英文别名: 2-ethyl-2H-indazole；2-Aethyl-2H-indazol；2-Aethyl-indazol；2-ethylindazole
• CAS: 43120-23-6
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: CUXVARDAJFAAHS-UHFFFAOYSA-N

物化性质

• 熔点：
  37-39 °C
• 沸点：
  140 °C(Press: 14 Torr)
• 密度：
  1.076 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethyl-2H-indazole 100.0 ℃ 、1.6 kPa 条件下， 生成 1-propyl-1H-indazole
  参考文献：
  名称：

  v. Auwers; Pfuhl, Chemische Berichte, 1925, vol. 58, p. 1366,1368

  摘要：

  DOI：
• 作为产物：
  描述：

  2-吲唑-2-基-丙酸 120.0~140.0 ℃ 、1.6 kPa 条件下， 生成 2-ethyl-2H-indazole
  参考文献：
  名称：

  v. Auwers; Allardt, Chemische Berichte, 1926, vol. 59, p. 98

  摘要：

  DOI：

文献信息

• IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Connolly Peter J.

  公开号：US20150099730A1

  公开（公告）日：2015-04-09

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L 1 , a, b, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein.

  公开了用于治疗多种疾病、综合征、状况和失调的化合物、组合物和方法，包括那些通过抑制脂肪酸合酶（FASN）酶介导的疾病，如癌症、肥胖或相关失调以及与肝脏相关的失调。这些化合物由公式（I）表示如下： 其中L1、a、b、m、n、R1、R2、R3、R4和R5在此定义。
• Reduction of nitro- and nitroso-compounds by tervalent phosphorus reagents. Part XI. A kinetic study of the effects of varying the reagent and the nitro-compound in the conversion of o-nitrobenzylideneamines to 2-substituted indazoles
  作者：Margaret-Ann Armour、J. I. G. Cadogan、David S. B. Grace

  DOI：10.1039/p29750001185

  日期：——

  A kinetic study of the effects of varying the phosphorus reagent and substituents in the nitro-compound in the reductive cyclisation of o-nitrobenzylideneamines to 2-substituted indazoles has been made. First-order rate constants vary from 8.2 to 52.2 × 10–5 s–1 for the triethyl phosphite-induced reduction of N-o-nitrobenzylideneanilines [o-NO2C6H4CHNC6H4Y; Y =p-MeO, p-Me, H, p-CI, p-Br, p-CO2Et, p-CN

  动力学研究了在邻硝基亚苄基胺还原成2-取代的吲唑的环化反应中改变硝基化合物中磷试剂和取代基的作用。一级速率常数从8.2变化至52.2×10 -5小号-1为的亚磷酸三乙酯诱导的减少ñ - ö -nitrobenzylideneanilines [ ø -NO 2 ç 6 ħ 4 CH NC 6 H ^ 4 ÿ; Y = p -MeO，p -Me，H，p -Cl，p -Br，p -CO 2等等，p -CN。p -NO 2，或ö ] -CI和Ñ -5-氯-2- nitrobenzylideneaniline，并略有不同的5至6×10 -5小号-1为ö -nitrobenzylideneamines [ ø -NO 2 ·C 6 H ^ 4 · CH NR; R = Me中，乙基，丙基我，或卜Ñ ]。这些反应的产物是相应的2-芳基-（芳基＝ C 6 H 4 Y）和2-烷基-（烷基＝ R）-吲唑。这
• N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
  申请人：——

  公开号：US20040002504A1

  公开（公告）日：2004-01-01

  The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: 1 wherein, generally, Q is 2 R 1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C 1-4 alkyl or halogen, such as methyl, fluorine or bromine; R 2 is hydrogen or C 1-4 alkyl such as methyl; R 3 is phenyl; R 4 is hydrogen; R 5 is hydrogen or C 1-6 alkylcarbonyl such as methylcarbonyl; X is —SO 2 — or —C(O)N(R 2 )SO 2 — where R 2 is preferably hydrogen; Y is a bond, CH 2 or Z 1 where Z 1 is —N(R f )— in which R f is C 1-6 alkylcarbonyl such as ethylcarbonyl; and R 6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C 1-6 alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗患有疾病（如精神分裂症）的受试者的方法，其中该疾病的治疗需要使用NK-3拮抗剂，包括向该受试者施用化合物I的治疗有效量： 1 其中，通常情况下， Q是 2 R 1 是苄基、苯基、噻吩或咪唑基，可选择地用C 1-4 烷基或卤素（如甲基、氟或溴）取代； R 2 是氢或C 1-4 烷基，如甲基； R 3 是苯基； R 4 是氢； R 5 是氢或C 1-6 烷基羰基，如甲基羰基； X是—SO 2 —或—C(O)N(R 2 )SO 2 —，其中R 2 最好是氢； Y是键、CH 2 或Z 1 ，其中Z 1 是—N(R f )—，其中R f 是C 1-6 烷基羰基，如乙基羰基；以及 R 6 是苯基、吡唑基、吡啶基、嘧啶基或苯并咪唑基，可选择地用来自C 1-6 烷基和苄基的一个或两个基团取代，如甲基、乙基和苄基； 或其药学上可接受的盐。
• Palladium‐Catalyzed Pyrazole‐Directed sp ³ C−H Bond Arylation for the Synthesis of β‐Phenethylamines
  作者：Nurbey Gulia、Olafs Daugulis

  DOI：10.1002/anie.201611407

  日期：2017.3.20

  have developed a method for palladium‐catalyzed, pyrazole‐directed sp3 C−H bond arylation by aryl iodides. The reaction employs a Pd(OAc)2 catalyst at 5–10 mol % loading and silver(I) oxide as a halide‐removal agent, and it proceeds in acetic acid or acetic acid/hexafluoroisopropanol solvent. Ozonolysis of the pyrazole moiety affords pharmaceutically important β‐phenethylamines.

  我们已经开发了一种通过芳基碘化物进行钯催化，吡唑定向的sp 3 C-H键芳基化的方法。该反应使用Pd（OAc）2催化剂，负载量为5-10 mol％，氧化银（I）作为卤化物去除剂，在乙酸或乙酸/六氟异丙醇溶剂中进行。吡唑部分的臭氧分解可提供具有药学重要性的β-苯乙胺。
• SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP3085695A1

  公开（公告）日：2016-10-26

  It is an object to provide a novel triazinone compound which has an inhibitory activity on a T-type voltage-dependent calcium channel, and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. A novel triazinone compound of Formula (I): wherein each substituent in the formula is defined in detail in the description, R4 means a hydrogen atom, or a C1-6 alkoxy group, etc., L1 and L2 each independently mean a single bond, or NR2, etc., L3 means a C1-6 alkylene group, etc., A means a C6-14 aryl group or a 5 to 10-membered heteroaryl group which may be substututed, B means a C3-11 cycloalkylene group, etc., D means a C6-14 aryl amino group or a 5 to 10-membered heteroaryl group which may be substituted, etc., a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt.

  提供一种新型三嗪酮化合物，其具有对T型电压依赖性钙通道的抑制活性，特别适用于预防或治疗疼痛、慢性肾病和房颤。公式（I）中的新型三嗪酮化合物：其中公式中的每个取代基在描述中有详细定义，R4表示氢原子或C1-6烷氧基等，L1和L2各自独立表示单键或NR2等，L3表示C1-6烷基等，A表示C6-14芳基或5至10环杂芳基，可取代，B表示C3-11环烷基等，D表示C6-14芳胺基或5至10环杂芳基，可取代等，化合物的互变异构体，化合物的药用可接受盐，化合物的溶剂化合物，互变异构体或药用可接受盐。